Arrowhead Pharmaceuticals — 2026 Fiscal Year-End Earnings Summary

Arrowhead Pharmaceuticals reported a net loss of $724.2 million for the fiscal year ended September 30, 2026, driven by a $215 million acquisition of a Priority Review Voucher and increased research and development expenses. The company's commercial product, REDEMPLO (plozasiran), expanded its market presence with new prescriptions growing 63% quarter-over-quarter and achieved marketing authorization in Germany and the United Kingdom for familial chylomicronemia syndrome. In clinical development, plozasiran demonstrated significant triglyceride reductions in Phase 3 trials for severe hypertriglyceridemia, while investigational candidates ARO-DIMER-PA and ARO-MAPT showed promising early results in targeting multiple genes and crossing the blood-brain barrier, respectively. Additionally, Arrowhead refinanced its credit facility to lower borrowing costs and announced a change in its fiscal year-end to December 31, effective January 1, 2027.